TG Therapeutics (NASDAQ:TGTX) Upgraded at StockNews.com

TG Therapeutics (NASDAQ:TGTX) was upgraded by equities researchers at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Tuesday.

TGTX has been the subject of several other research reports. JPMorgan Chase & Co. boosted their price objective on TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research report on Monday, November 25th. HC Wainwright reiterated a “buy” rating and set a $55.00 price target on shares of TG Therapeutics in a report on Tuesday. Finally, The Goldman Sachs Group raised their price objective on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, TG Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.67.

TG Therapeutics Stock Performance

Shares of NASDAQ:TGTX traded up $1.20 during trading on Tuesday, reaching $35.62. The stock had a trading volume of 4,498,231 shares, compared to its average volume of 2,491,593. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The stock has a fifty day simple moving average of $30.86 and a two-hundred day simple moving average of $28.33. The firm has a market capitalization of $5.54 billion, a price-to-earnings ratio of -356.16 and a beta of 2.30. TG Therapeutics has a 52 week low of $12.93 and a 52 week high of $36.94.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm had revenue of $108.19 million for the quarter, compared to the consensus estimate of $100.67 million. As a group, analysts anticipate that TG Therapeutics will post 0.08 earnings per share for the current fiscal year.

Insider Buying and Selling at TG Therapeutics

In other TG Therapeutics news, CFO Sean A. Power sold 10,021 shares of TG Therapeutics stock in a transaction on Monday, January 6th. The shares were sold at an average price of $28.53, for a total transaction of $285,899.13. Following the sale, the chief financial officer now owns 660,611 shares in the company, valued at $18,847,231.83. The trade was a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 10.50% of the company’s stock.

Hedge Funds Weigh In On TG Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in shares of TG Therapeutics by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 15,596,480 shares of the biopharmaceutical company’s stock valued at $469,454,000 after acquiring an additional 209,190 shares in the last quarter. State Street Corp lifted its stake in TG Therapeutics by 35.8% during the third quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company’s stock worth $212,712,000 after purchasing an additional 2,398,015 shares during the period. Soleus Capital Management L.P. grew its stake in shares of TG Therapeutics by 5.8% in the 4th quarter. Soleus Capital Management L.P. now owns 2,681,242 shares of the biopharmaceutical company’s stock valued at $80,705,000 after purchasing an additional 146,702 shares during the period. Clearbridge Investments LLC bought a new stake in shares of TG Therapeutics in the 4th quarter valued at approximately $55,237,000. Finally, Northern Trust Corp raised its holdings in shares of TG Therapeutics by 8.6% in the 4th quarter. Northern Trust Corp now owns 1,532,929 shares of the biopharmaceutical company’s stock worth $46,141,000 after buying an additional 120,785 shares in the last quarter. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.